Risk Mediation in Association Rules:

Similar documents
A Comparison of Collaborative Filtering Methods for Medication Reconciliation

Medication review in Parliament. HARM study (2006) Medication review in the Netherlands. HARM study Recommendations. HARM study Risk factors

High-level Vision. Bernd Neumann Slides for the course in WS 2004/05. Faculty of Informatics Hamburg University Germany

Hypothesis-Driven Research

Selecting the right patient for medication reviews

Deprescribing: A Practical Guide

Safe, effective, affordable drug choices: online tool for payers and patients.

How to use PRECIS-2 - Designing trials that are fit for purpose

March 2010, 15 male adolescents between the ages of 18 and 22 were placed in the unit for treatment or PIJ-prolongation advice. The latter unit has

Exploiting Similarity to Optimize Recommendations from User Feedback

THE ADVANCED MEDICATION REVIEW

Around fifteen semi-structured interviews are going to be conducted with specialist physicians of the domains selected for the checklist.

Clinical risk management in community pharmacy - Henk Buurma SUMMARY

Drug Misuse and Dependence Guidelines on Clinical Management

Management of patients with multimorbidity: the perspective of primary care

A Case Study on Visual Analytics for Optimizing Drug Duplicate Alerts in a Medication Clinical Decision Support System

A Decision Support System for Polyuria Patient s Treatment

PCNE 3rd Medication Review Workshop 1

Chapter 02 Developing and Evaluating Theories of Behavior

Polymedication in nursing home. Graziano Onder Centro Medicina dell Invecchiamento Università Cattolica del Sacro Cuore Rome - Italy

PGEU GPUE. Pharmaceutical Group of European Union Groupement Pharmaceutique de l Union Européenne

Medication Management When Caring for Seniors at Home

Online Supplementary Material

Detecting inappropriate prescribing for older patients at the community pharmacy

How to Create Better Performing Bayesian Networks: A Heuristic Approach for Variable Selection

On the Combination of Collaborative and Item-based Filtering

Appearance before House of Commons Standing Committee on Health as part of its Study on the Government s Role in Addressing Prescription Drug Abuse

Student Social Worker (End of Second Placement) Professional Capabilities Framework Evidence

Lecture 9 Internal Validity

The SIMPATHY economic analysis tool

Le politerapie complesse: l'arte del deprescribing. Andrea Corsonello IRCCS INRCA - Cosenza

The Home Office Proposals to schedule pregabalin and gabapentin under the Misuse of Drugs Regulations 2001 January 2018

Reflection paper on assessment of cardiovascular risk of medicinal products for the treatment of cardiovascular and metabolic diseases Draft

Recommendations from the Devon Prisons Health Needs Assessment. HMP Exeter, HMP Channings Wood and HMP Dartmoor

January 19, Cannabis Legalization and Regulation Secretariat Address locator 0602E Health Canada Ottawa, Ontario K1A 0K9

Nature and significance of the local problem

CDC Guideline for Prescribing Opioids for Chronic Pain. Centers for Disease Control and Prevention National Center for Injury Prevention and Control

Olanzapine Long Acting Injection (LAI) Guideline

STIN2103. Knowledge. engineering expert systems. Wan Hussain Wan Ishak. SOC 2079 Ext.: Url:

SCHEDULE 2 THE SERVICES. A. Service Specifications

CRITICAL APPRAISAL OF CLINICAL PRACTICE GUIDELINE (CPG)

Open Research Online The Open University s repository of research publications and other research outputs

Group Assignment #1: Concept Explication. For each concept, ask and answer the questions before your literature search.

Models of Information Retrieval

Systematic Reviews and Meta- Analysis in Kidney Transplantation

ADVANCES ON RISK ASSESSMENT FOR ALLERGENS IN FOOD: AN OVERVIEW AND SUPPORTING TOOLS

Tim Kelly. High Integrity Systems Engineering Group Department of Computer Science

Stronger together - optimizing pharmacotherapy on geriatric wards?

Evaluating Classifiers for Disease Gene Discovery

Outline. What s inside this paper? My expectation. Software Defect Prediction. Traditional Method. What s inside this paper?

Improving medication safety

Procedure Reviewed By: Narinder Sangha Deputy Chief Pharmacist STANDARD OPERATING PROCEDURE

C. A. K. van der Stelt 1 A. M. A. Vermeulen Windsant-van den Tweel. A. C. G. Egberts 2,3 P. M. L. A. van den Bemt

Optimizing medication in caring for seniors living with frailty: Five perspectives

Prescription Medication Guidelines for Medical Providers in CorVel s CorCare and Care IQ Networks

Industry Perspective on Formulation and Packaging Considerations

Submitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis

DOWNLOAD OR READ : VULNERABLE OLDER ADULTS PDF EBOOK EPUB MOBI

SCHEDULE 2 THE SERVICES. A. Service Specifications

SFHPT24 Undertake an assessment for family and systemic therapy

Candidate Information Sheet Therapeutic Decision Making Examination For Practice Ready Assessment (PRA) Selection Process

Identifying Parkinson s Patients: A Functional Gradient Boosting Approach

FDAP Drug & Alcohol Professional Certification Workplace Assessment

AUSTRALIAN AND NEW ZEALAND COLLEGE OF ANAESTHETISTS ABN

Exploring and Validating Surrogate Endpoints in Colorectal Cancer. Center, Pittsburgh, USA

There s A Pill For That (But should my patient be on it?) A Review of Tools for the Evaluation of Optimal Prescribing in Geriatric Patients

What Is Science? Lesson Overview. Lesson Overview. 1.1 What Is Science?

MINI GRANT PROJECT SUMMARY

2015 UK Parkinson s Audit Patient and carer report

Evidence-Based Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine in People with Dementia

Can a person taking valium drive a car

Effective Values of Physical Features for Type-2 Diabetic and Non-diabetic Patients Classifying Case Study: Shiraz University of Medical Sciences

Clinical Pharmacology and Therapeutics

Stepwise Knowledge Acquisition in a Fuzzy Knowledge Representation Framework

Module 3 - Scientific Method

Empowering Older Adults On Drug Adherence A Collaborative Service Model. Cheng Po-po, Peggy Nurse Consultant (Gerontology) Yan Chai Hospital, KWC, HA

Drugs & Alcohol Misuse Guidelines 2017

IPT ADHERENCE AND QUALITY SCALE

Overview of Technology-Assisted HSB Practice Guidance. Richard Swann, Social Worker and Associate AIM Project, UK.

Research Prospectus. Your major writing assignment for the quarter is to prepare a twelve-page research prospectus.

Visual book review 1 Safe and Sound, AI in hazardous applications by John Fox and Subrata Das

Focusing the question

Advanced Practitioner Physiotherapist (APP) as first point of contact in GP Surgeries

Getting the best from the medicines you buy

How do I comply with the Influenza Control Program Policy this year?

Commentary on Beutler et al. s Common, Specific, and Treatment Fit Variables in Psychotherapy Outcome

From medicines reconciliation to medicines review. Dr. Fatma Karapinar Hospital pharmacistepidemiologist

Data Mining in Bioinformatics Day 4: Text Mining

Research Article A Hybrid Genetic Programming Method in Optimization and Forecasting: A Case Study of the Broadband Penetration in OECD Countries

Cover images courtesy of jk1991 at FreeDigitalPhotos.net Infographics courtesy of SIMPATHY consortium

6. A theory that has been substantially verified is sometimes called a a. law. b. model.

The All Wales Medicine Strategy Group (AWMSG) is asked to support implementation of the following prescribing indicators.

Risk Interpretation and Action

Cognitive domain: Comprehension Answer location: Elements of Empiricism Question type: MC

INFERENCING STRATEGIES

extraction can take place. Another problem is that the treatment for chronic diseases is sequential based upon the progression of the disease.

PHARMACY INTERVENTION RECORD FORM 1.7 Medicine

duplicate safe reliable same medicine, different name good brands switch Answers to questions about generic medicines generic medicines

Physicians and possibly medical students and paramedics.

Work package 6, task 2: Review existing care (pathway) approaches for multi-morbidity patients

Transcription:

Risk Mediation in Association Rules: The Case of Decision Support in Medication Review Michiel C. Meulendijk 1, Marco R. Spruit 2, Sjaak Brinkkemper 2 1 Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, the Netherlands m.c.meulendijk@lumc.nl 2 Department of Information and Computing Sciences, Utrecht University, Utrecht, the Netherlands m.r.spruit@uu.nl, s.brinkkemper@uu.nl Abstract. We propose a model for the incorporation of risk in association rule application. We validate this model using data gathered in a randomized controlled trial from a recommender system for medication reviews in primary care. The model s outcomes are found to have predictive value when tested against decisions made by physicians on 261 patients health records. Keywords: Association Rules, Decision Support, Risk Management 1 Introduction Association rule mining remains one of the most prominent knowledge discovery methods in existence. Association rules have been implemented in countless software applications in a wide variety of domains, including the domain of primary care [1]. The typical example of association rule implementation, the market basket, reveals one of its weaknesses: grocery items that are frequently purchased together form an association rule, which is used for personalized adverts. In a safe, insensitive domain such as shopping this poses no problems, but in a precarious domain with vulnerable datasets, where association rules can have potentially far-reaching implications, these kinds of associative suggestions are risky. Therefore, in this paper we propose a model for the incorporation of risk in association rules. We implement and validate it in a primary care setting. 2 Background 2.1 Recommender Systems in Precarious Domains The impact association rules may have depends on the sensitivity of the dataset on which they are applied. This danger involved in applying discovered association rules to sensitive datasets in precarious domains has not received substantial attention. For

the remainder of this paper, we define precarious domains as domains in which association rules consequences have potentially major impact on its datasets. An example of a precarious domain is that of primary care. 2.2 Risk As A Post-Mining Metric Risk management involves a set of coordinated activities to direct and control an organization with regard to risk. Risk is typically understood as the probability of loss in any given situation, or, in a more generic definition, the effect of uncertainty on objectives. In risk management, risk is usually incorporated as a function of these uncertain effects impact and their likelihood of occurring. Association rules and risk share the concept of probability; association rules are expressed with a degree of confidence, while risk incorporates the likelihood of dangerous consequences. While association rules impact is not a standardized concept, the implications their consequences have imply its risk s severity. Table 1. Relations between association rules characteristics and risk. Risk Probability Rule Impact High Low High? High Risk Low? Low Severity Low High Rule Confidence 3 Risk Model Formulation Recommender systems, whether powered by explicit knowledge bases or implicit content-based or collaborative-based filtering, depend on inference rules. Inference rules are logical functions which analyze premises and, based on their syntax, return conclusions. Recommender systems depend on datasets containing all relevant items to trigger their inference rules. In propositional logic inference rules can be written as x y, with a dataset D = {d 1,, d n } and x D. Thus, for a specific rule dataset D contains its premises, along with other items, but never its consequence. The risk associated with a rule is a function of its unwanted consequences and their likelihood of occurring. The formula to determine the risk of an inference rule x y reads: risk(x y) = (1 probability(x y)) i=d,y severity(i) (1)

The probability of the consequences being unacceptable is one minus the confidence with which the rule is accepted. In the case of association rules that have been discovered using common algorithms, the probability in the formula is equal to its confidence. The severity of a rule s risk is the sum of the impact of the objects associated with it. This comprises not just the danger associated with the inference s consequence y, but also detrimental characteristics of items in dataset D; it may be riskier to perform a certain action on a vulnerable dataset than on a safer one. The danger associated with these items can be estimated through risk formulas as well. As such, when implemented in a domain, the final formula results in the sum of its associated objects risks, multiplied with its rule s inverse probability. 4 Implementation The above-mentioned formulae are demonstrated and validated by applying them to the STRIP Assistant (STRIPA), a recommender system for medication reviews in primary care [1]. STRIPA s hybrid rule base consists of guidelines and inference rules acquired through association rule mining, and has been shown to be effective [2]. 4.1 Health Records Risk The dataset in STRIPA consists of a patient s health record. The items in this dataset, such as diseases or drugs, serve as premises for the system s inference rules. All inference rules modify one or more drugs by prescribing new medicines, removing existing ones, or adjusting their dosages. A dataset D comprising a certain patient s diseases, drugs, contra-indications, allergies, and measurements can be described as a set: disease 1,, disease k ; drug 1,, drug l ; contraindication D = { 1,, contraindication m ; measurement 1,, measurement n ; } (2) allergy 1,, allergy p Following x D and the fact that all inference rules adjust drugs, the implemented risk formula reads: risk(x drug) = (1 probability(x drug)) (severity(d) + severity(drug)) (3) 4.2 Health Records Severity Determining the risk associated with a patient s health record, or dataset, involves taking into account a multitude of domain-dependent variables, such as his or her age, frailty, physical properties, and cognitive state. This results in the severity of a dataset D being the sum of its domain-relevant, patient-specific, risk factors:

severity(d) = riskfactor D riskfactor (4) The Dutch multidisciplinary guideline for polypharmacy in elderly people 1 proposes seven factors that increase patients risk of harm due to inappropriate drug use: age (over 65 years old), polypharmacy (using four or more drugs simultaneously), impaired renal function, impaired cognition, frequent falling, decreased therapy adherence, and living in a nursing home. In this study s dataset, four of these risk factors were available: age, polypharmacy, impaired renal function, and impaired cognition. 4.3 Drug Severity A drug s severity can be expressed as a function of its dose, or toxicity, and its adverse effects, or harm: severity(drug) = toxicity(drug) harm(drug) (5) An adverse effect is a response to a drug that is noxious and unintended and occurs at normal doses. These effects are usually classified in terms of their likelihood of occurring. Their frequency and potential impact are used to determine drugs safety for prescribing. As such, the function of the number of adverse effects a drug has and their frequency can be useful to determine a substance s potential harm: harm(drug) = e E e. frequency (6) The sets of adverse effects, defined per active substance, were retrieved from a database maintained by the Royal Dutch Pharmacists Association 2. Adverse effects are classified due to their likelihood of occurring: often (over 30% of patients or more), sometimes (10%-30% of patients), rarely (1%-10% of patients), and very rarely (less than 1% of patients). As such, each drug s adverse effects can be described as a set E = {e 1,, e n }, where e i = (id, freqency). The definition provided for adverse effects also takes into account the prescribed dosage, something not accounted for in the formula above. Research has shown that the probability of adverse effects generally increases with higher dosages being used. For each drug, the World Health Organization has defined an average strength with which it is typically prescribed. This Defined Daily Dose 3 (DDD) is the assumed average maintenance dose per day for a drug used for its main indication in adults. Dividing a patient s actual daily dosage of a drug by the DDD provides a factor that can be used to relativize the drug s risk. Its toxicity can thus be calculated as such: toxicity(drug) = prescribeddailydose(drug) defineddailydose(drug) (7) 1 https://www.nhg.org/themas/publicaties/ multidisciplinaire-richtlijn-polyfarmacie-bij-ouderen 2 http://www.apotheek.nl/medicijnen 3 http://www.whocc.no/ddd/definition_and_general_considera/

5 Validation The risk model was validated by comparing its predictions with actual actions taken by experts. STRIPA was used on real patient cases by dedicated teams of GPs and pharmacists for the duration of a year as part of a randomized controlled trial, which was performed in 25 general practices in Amsterdam, the Netherlands and included 500 patients [3]. For the 261 of these patients that were placed in the intervention arm, four teams consisting of one GP and one pharmacist each used the software to optimize their medical records. The users would respond to patient-specific advice, recommending them to prescribe new drugs for particular diseases. Their responses to advices were gathered; each time a suggestion was heeded or ignored, the instance, along with relevant patient case information, was logged. A total of 776 responses to advices, of which 311 were heeded, has been gathered and will be used to validate the risk model. Assuming that users will strive for the minimization of risk, we hypothesize that users will have chosen the least risky option whenever possible. Based on the assumption that riskier patients i.e. patients who have multiple risk factors in their dataset (or health record) are best served with as little change to their drug regimen as possible, it was hypothesized that the higher an action s risk was, the least likely it was to be performed by users. To test this, the risk factors of each generated recommendation were calculated; its proposed drug s risk and the relevant patient s risk factors were summed according to the introduced model. An independent t-test affirmed the hypothesis, showing a statistical difference in the risk associated with proposed actions which were followed (M = 2.42, SD = 0.57) and the risk of proposed actions which were not followed (M = 2.57, SD = 0.60); t(623) = 3.040, p =.002. 6 Conclusion In this study, we explored the potential usefulness of the concept of risk in association rules. Validation shows that the risk model has predictive power in the domain of medication reviews. Application examples can be found in a technical report [4]. We would like to thank Pieter Meulendijk for his contributions to the conceptual model following his expertise in risk management. References 1. M. Meulendijk et al., "STRIPA: A Rule-Based Decision Support System for Medication Reviews in Primary Care," in Proceedings of ECIS 2015, Münster, Germany, 2015. 2. M. Meulendijk et al., "Computerized decision support improves medication review effectiveness: an experiment evaluating the STRIP Assistant's usability," Drugs & Aging, 1-9, 2015. 3. M. Meulendijk et al., "Efficiency of clinical decision support systems improves with experience," Journal of Medical Systems, vol. 40, no. 4, 1-7, 2016. 4. M. Meulendijk, M. Spruit and S. Brinkkemper, "Risk Mediation in Association Rules: Application Examples," Utrecht University, UU-CS-2017-004, 2017.